PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsUrinary incontinence
MeSH D014549 - urinary incontinence
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D014555:Urination disorders
$
Success rate
D059411:Lower urinary tract symptoms
0 Companies
0 Drugs
Success rate
D014549: 
Urinary incontinence
$
Success rate
D014550:Stress urinary incontinence
$
Success rate
D053202:Urge urinary incontinence
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaOxybutynin Kentera (previously Oxybutynin Nicobrand)  2004-06-15   
Oxybutynin Oxybutynin  1988-11-14   
Tolterodine Tolterodine  2015-02-23   
Novast LaboratoriesOxybutynin Oxybutynin  2019-10-30   
MylanOxybutynin Oxybutynin  2006-11-09   
Tolterodine Tolterodine  2012-11-27   
Johnson & JohnsonOxybutynin Ditropan  1982-01-01   
AlpharmaHydrocodone, Phenylpropanolamine Codamine  2000-09-29   
AllerganOxybutynin Gelnique 2022-06-25 2011-12-07   
Oxybutynin Oxytrol  2003-02-26   
Oxybutynin Oxybutynin  1989-04-19   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
100%
4/4
Phase 2
70%
7/10
Phase 3
71%
12/17
Approved: 6Overall Success rate: 49%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Padagis
Mylan
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use